In a retrospective case study conducted at a Colorado mental health facility, researchers found cannabidiol (CBD) may hold benefits for anxiety-related disorders.
The researchers published their findings in an article appearing in the peer-reviewed Permanente Journal. The article is “Cannabidol in Anxiety and Sleep: A Large Case Series” and can be found by clicking here.
In their article, researchers Scott Shannon, MD, Nicole Lewis, ND, Heather Lee, PA-C, and Shannon Hughes, PhD, reported applying CBD clinically to psychiatric patients complaining of anxiety and sleep concerns.
In the sample study of 72 adults, anxiety decreased within the first month in 57 patients (79.2%) and remained decreased for the study’s duration. Sleep scores improved within the first month in 48 patients (66.7%) but fluctuated over time.
The researchers said CBD was well tolerated in all but three patients, and recommended that controlled clinical trials be conducted.
Asterra Labs is one of just 10 CBD brands — out of more than 3,500 CBD brands found in the marketplace — currently participating in a clinical trial.
The study, managed by ValidCare, is being conducted in response to the U.S. Food and Drug Administration’s request for science-based quantifiable data about the safety of full-spectrum, hemp-derived CBD and CBD isolate.
Learn more about the trial and the role of Asterra Labs by clicking here.